Treatment alternatives for multidrug-resistant fungal pathogens

Related Experiment Video

Updated: Aug 2, 2025

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance
08:45

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance

Published on: December 28, 2017

13.8K

Kevin Roe1

  • 1San Jose, CA, USA.

Drug Discovery Today
|April 22, 2023
PubMed

Insights

New treatments for drug-resistant fungal infections are needed. Alternative therapies like fungal vaccines, monoclonal antibodies (mAbs), or mRNA-based therapies offer promising advantages over current antifungal drugs.

Area of Science:

  • Mycology
  • Immunology
  • Infectious Diseases

Background:

  • Increasing antimicrobial resistance in fungal pathogens necessitates novel therapeutic strategies.
  • Multidrug-resistant fungal infections pose a significant global health challenge.

Purpose of the Study:

  • To explore alternative treatment modalities for fungal infections beyond conventional antifungal drugs.
  • To investigate the potential of vaccines, monoclonal antibodies (mAbs), and mRNA-based therapies in combating resistant fungal pathogens.

Main Methods:

  • Review of existing literature on fungal resistance and alternative treatment development.
  • Conceptualization of therapeutic approaches involving synthesized proteins, mAbs, and mRNA delivery systems.
  • Consideration of combination therapies integrating antifungal drugs with novel immunotherapies.

Main Results:

  • Fungal vaccines present a viable strategy for prophylaxis and treatment.
  • Conventional or synthetic monoclonal antibodies (mAbs) can target specific fungal surface proteins.
  • In vivo production of mAbs via mRNA injections offers a novel therapeutic avenue.

Conclusions:

  • Alternative treatments, including vaccines and mAb-based therapies (direct or mRNA-induced), show significant potential.
  • Targeting fungal surface proteins with synthesized molecules or mAbs can effectively inhibit infections.
  • Combination therapies may enhance efficacy against multidrug-resistant fungal strains.
Keywords:
fungal infectionsfungal pathogensimmune cellsmonoclonal antibodiesproteinssynthetic monoclonal antibodies

More Related Videos

Bio-energetics Investigation of Candida albicans Using Real-time Extracellular Flux Analysis08:48

Bio-energetics Investigation of Candida albicans Using Real-time Extracellular Flux Analysis

Published on: March 19, 2019

7.0K
Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

598

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
219
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
4.2K
Fungal Phylum Microsporidia01:28

Fungal Phylum Microsporidia

Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
43
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
405